|
|||||
|
|
Excess risk of hip fractures attributable to the use of antidepressants in five European countries and the USA |
|
| Authors: | D Prieto-Alhambra H Petri J S B Goldenberg T P Khong O H Klungel N J Robinson F de Vries |
| Institution: | 1. Oxford National Institute for Health and Research (NIHR) Musculoskeletal Biomedical Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK 10. Musculoskeletal Research Group, IMIM-Parc de Salut Mar, Barcelona, Spain 2. Medical Research Council (MRC) Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK 9. GREMPAL Research Group, IDIAP Jordi Gol, Primary Care Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain 3. Epidemiology and Patient Reported Outcomes, Roche Products Limited, Shire Park, 6 Falcon Way, Welwyn Garden City, AL7 1TW, UK 4. Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, Utrecht, The Netherlands 5. Abbott Healthcare Products B.V., Weesp, The Netherlands 6. Epidemiology and Patient Reported Outcomes, Hoffman-La Roche, Building 663, Grenzacherstrasse 124, 4070, Basel, Switzerland 7. Department of Clinical Pharmacy & Toxicology, Maastricht University Medical Centre, Maastricht, Netherlands 8. CAPHRI School for Public Health and Primary Care, Maastricht, The Netherlands |
| Abstract: | SummaryThe association between antidepressant use and hip fracture remains unclear. We conducted a systematic review to estimate Population Attributable Risks (PAR) for France, Germany, Italy, Spain, UK, and the USA. We report a heterogeneous prevalence of antidepressant use and related PARs, both lowest for Italy and highest for the USA.IntroductionAntidepressant use has been associated with an increased hip fracture risk in observational studies. However, the potential contribution of antidepressant consumption on the population rate of hip fractures has not been described. Our aim was to estimate the impact of the use of different classes of antidepressants on the rate of hip fracture at a population-level in France, Germany, Italy, Spain, the UK, and the USA.MethodsWe conducted a systematic literature review to estimate the pooled relative risk (RR) of hip fracture according to use of antidepressants. Prevalence rates of antidepressant use (Pe) in 2009 were calculated for each country using the The Intercontinental Medical Statistics database and three public databases from Denmark, the Netherlands, and Norway. Both the RR and Pe were used to calculate PAR of hip fractures associated with antidepressant use.ResultsThe literature review showed an increased risk of hip fractures in antidepressant users (RR, 1.7; 95 % confidence interval (CI), 1.5–2.0). Rates of antidepressant use showed considerable differences between countries, ranging from 4.4 % (Italy) to 11.2 % (USA) in the year 2009. The estimated PAR of antidepressants on hip fracture rates were 3.0 % (95 % CI, 2.0–4.1; Italy), 3.1 % (95 % CI, 2.1–4.3; Germany), 3.8 % (95 % CI, 2.6–5.3; France), 4.8 % (95 % CI, 3.3–6.5; Spain), 4.9 % (95 % CI, 3.4–6.8; UK), and 7.2 % (95 % CI, 5.0–9.9; USA). PARs differed for different types of antidepressants, with highest attributable risks for selective serotonin reuptake inhibitors.ConclusionsThese findings suggest that the potential contribution of antidepressant use to the population rate of hip fractures in the five large EU countries and the USA varies between 3 and 7 %. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |